Three studies presented at the American Society of Hematology (ASH) 58th Annual Meeting held in San Diego, California, US highlight the use of chimeric antigen receptor (CAR) T cell therapy for the treatment of refractory adult and paediatric lymphoma and leukaemia.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Cancer patients who have undergone successful treatment may have increased risk of developing therapy-related myeloid neoplasms (t-MNs), a fatal form of secondary malignancy, even after years of successful treatment, according to a recent study presented at the ASH 58th Annual Meeting in San Diego, California, US.
Lenalidomide maintenance therapy reduces the risk of progression by more than 80 percent in patients with high-risk chronic lymphocytic leukaemia (CLL) who responded to first-line chemoimmunotherapy, interim results of the phase III CLL M1 study have shown.
Obinutuzumab reduces the risk of disease progression by about one-third in patients with advanced follicular lymphoma (FL) compared with rituximab, interim results of the phase III GALLIUM study have shown.